Clinical Trials Directory

Trials / Unknown

UnknownNCT03713749

Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial

Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) : a Multicenter Open-label Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
212 (estimated)
Sponsor
Chang Gung Memorial Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The investigators will assess the adequacy of nodal dissection along the recurrent laryngeal nerve performed with robot-assisted versus video-assisted thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma through a prospective multicentre randomized study design.

Detailed description

Radical lymph node dissection (LND) along the recurrent laryngeal nerve (RLN) is surgically demanding and can be associated with substantial postoperative morbidity. The question as to whether robot-assisted esophagectomy (RE) might be superior to video-assisted thoracoscopic esophagectomy (VATE) for performing LND along the RLN in patients with esophageal squamous cell carcinoma (ESCC) remains open. The investigators will conduct a multicenter, open-label, randomized controlled trial (termed REVATE) enrolling patients with ESCC scheduled to undergo LND along the RLN. Patients will be randomly assigned to either RE or VATE. The primary outcome measure will be the rate of unsuccessful LND along the left RLN, which will be defined as 1) failure to remove lymph nodes along the left RLN or 2) occurrence of left RLN palsy following LND. Secondary outcomes will include the number of successfully removed RLN nodes, postoperative recovery, length of hospital stay, 30- and 90-day mortality, quality of life, and oncological outcomes.

Conditions

Interventions

TypeNameDescription
DEVICERobot esophagectomy (RE)Patients in RE group will receive Robotic-assisted surgery in thoracic phase.

Timeline

Start date
2018-10-22
Primary completion
2022-04-22
Completion
2022-12-22
First posted
2018-10-22
Last updated
2021-07-01

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03713749. Inclusion in this directory is not an endorsement.